Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Int J Obes (Lond). 2021 Oct 29;46(2):333–341. doi: 10.1038/s41366-021-01005-y

Table 1. Clinical characteristics of BOCABS Study participants pre- and post-RYGB and of non-obese Controls.

Obese pre-RYGB (n=22) Obese post-RYGB (n=22) Non-obese Controls (n=20) P-value; pre-RYGB vs Controls P-value; pre- vs post-RYGB
Age (years)* 47 (1.2) - 46 (2.6) 0.720 -
Sex N (%)
  Female 18 (82) - 12 (60) 0.175 -
  Male 4 (18) - 8 (40)
Smoking N
  Daily 0 1 5 0.002 <0.001
  Occasional 0 11 1
  Ex-smoker 11 9 2
  Never smoked 10 0 12
  Missing data 1 1 0
NSAID Administration N
  Yes 10 1 5 0.209 0.004 §
  No 12 21 15
Cholecystectomy N
  Yes 4 0 2 0.665 -
  No 18 22 18
Diabetes Mellitus N
  Yes 4 2 0 0.679 1.0§
  No 18 19 9
  Missing data 0 1 11
Weight (kg)* 114.8 (3.7) 87.7 (3.5) 71.8 (2.8) <0.001 <0.001
BMI (kg/m2)* 41.7 (1.4) 31.8 (1.1) 25.4 (0.5) <0.001 <0.001
Body fat (%)* 47.6 (1.0) 36.5 (1.5) 30.3 (1.3) <0.001 <0.001
Waist: Hip ratio* 0.92 (0.0) 0.87 (0.0) 0.86 (0.0) 0.039 0.001
  Female 0.89 (0.0) 0.84 (0.0) 0.82 (0.0) 0.010 0.007
  Male 1.07 (0.0) 0.99 (0.0) 0.93 (0.0) 0.001 0.067
FPG (mmol/L)* 5.8 (0.4) 4.9 (0.4) 4.5 (0.1) 0.003 0.001
hsCRP (mg/L)* 5.5 (0.9) 1.6 (0.4) 3.6 (1.2) 0.190 <0.001
HbA1c (mmol/-mol)* 42.2 (2.9) 38.5 (2.4) 36.6 (0.8) 0.194 0.001
Insulin (pmol/L)* 117.1 (19.6) 54.3 (7.8) 64.6 (10.6) 0.025 0.001
HOMA-IR* 2.1 (0.4) 1.0 (0.1) 1.2 (0.2) 0.014 <0.001
Leptin (ng/mL)* 62.5 (14.3) 15.6 (3.9) 11.2 (3.2) 0.002 0.003
*

Data presented as Mean (SEM)

Fisher’s exact test

§

Related sample McNemar test

An unpaired t-test was used for comparisons between pre-RYGB and non-obese Controls unless otherwise stated as ¶ Mann-Whitney U test for non-parametric data

A paired t-test was used for comparison between pre- and post-RYGB unless otherwise stated as ‡Wilcoxon signed rank test for non-parametric data

FPG, Fasting Plasma Glucose; hsCRP, high sensitivity C-reactive protein; HbA1c, haemoglobin A1c; HOMA-IR, homeostasis model assessment insulin resistance.